Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Genome Med
Prif Awduron: Chalmers, Zachary R., Connelly, Caitlin F., Fabrizio, David, Gay, Laurie, Ali, Siraj M., Ennis, Riley, Schrock, Alexa, Campbell, Brittany, Shlien, Adam, Chmielecki, Juliann, Huang, Franklin, He, Yuting, Sun, James, Tabori, Uri, Kennedy, Mark, Lieber, Daniel S., Roels, Steven, White, Jared, Otto, Geoffrey A., Ross, Jeffrey S., Garraway, Levi, Miller, Vincent A., Stephens, Phillip J., Frampton, Garrett M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395719/
https://ncbi.nlm.nih.gov/pubmed/28420421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0424-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg